Santhera Pharmaceuticals has received reimbursement approval from the Italian Medicines Agency (AIFA) for AGAMREE® (vamorolone), a novel treatment for Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. This decision, following a positive evaluation by AIFA’s Board on April 22, 2026, is part of a broader strategy to enhance access to AGAMREE across major European markets, including successful launches in Germany, Austria, and the UK. The reimbursement will take effect following its formal publication in the Italian Official Gazette.

The significance of AGAMREE lies in its unique pharmacological profile as a dissociative corticosteroid, which selectively binds to the glucocorticoid receptor to exert anti-inflammatory effects while mitigating the adverse effects commonly associated with traditional glucocorticoids. In the pivotal Phase 2b VISION-DMD study, AGAMREE demonstrated a statistically significant improvement in Time to Stand (TTSTAND) velocity compared to placebo, with a p-value of 0.002. Long-term data presented at the Muscular Dystrophy Association Clinical & Scientific Conference highlighted AGAMREE’s potential to offer comparable efficacy to standard corticosteroids while presenting a differentiated safety profile, including a significantly lower incidence of vertebral fractures and cataracts.

The approval and anticipated reimbursement of AGAMREE may shift current research paradigms in DMD treatment, particularly regarding the development of therapies that prioritize safety and efficacy. As AGAMREE becomes available in more markets, it could accelerate the transition toward innovative treatment strategies that reduce the long-term complications associated with conventional corticosteroid therapies. This development not only enhances the therapeutic landscape for DMD but also sets a precedent for future drug development in rare neuromuscular diseases.

Source: globenewswire.com